Eli Lilly
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 8 | 4 | live | 6 | 12 |
| Research labs and data | 5 | 2 | funded or contracted | 1 | 13 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Eli Lilly scores 8 out of 10 for priority and 4 out of 10 for delivery on AI in drug discovery, at the live stage, with Lilly TuneLab giving biotech companies access to Lilly's AI drug discovery models and an NVIDIA DGX SuperPOD supercomputer for its scientists. On research labs and data it scores 5 out of 10 for priority and 2 out of 10 for delivery, at the funded or contracted stage, based on a co-innovation lab with NVIDIA to connect Lilly's agentic wet labs with computational dry labs in which the two companies will invest up to $1 billion over five years. Six AI in drug discovery commitments were made public in the last 12 months and six in the year before; the recent ones include agreements with Insilico Medicine, Chai Discovery, BigHat Biosciences and Profluent and the expansion into the LillyPod AI factory and NVIDIA co-innovation lab. That co-innovation lab is the only research labs and data commitment made public in the last 12 months, with none in the year before. On 6 October 2026, 12 R&D roles were open in AI in drug discovery and 13 in research labs and data, many of them in lab automation and agentic automation, with Hamilton, Tecan and Opentrons named among the lab systems in use.
AI in drug discovery
What the company says: Priority 8
We pursued breakthrough discoveries on three fronts. ... Partnerships were forged to deploy AI to help decode biology, with the potential to accelerate the discovery of new treatments
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA
The supercomputer is the world's first NVIDIA DGX SuperPOD with DGX B300 systems. It is powered by more than 1,000 B300 GPUs on a unified networking fabric
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, 28 Oct 2025
Scientists will be able to train AI models on millions of experiments to test potential medicines, dramatically expanding the scope and sophistication of drug discovery efforts.
The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance, 4 Feb 2026
Opened Gateway Lab in Philadelphia and launched TuneLab for AI-enabled drug discovery
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
Drove initiatives including NVIDIA AI supercomputer partnership
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
What it shows running: Delivery 4, live
Launched a platform, giving biotechnology companies access to artificial intelligence (AI)-enabled drug discovery models.
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
Lilly TuneLab, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities including advanced AI models.
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia, 19 Nov 2025
Lilly TuneLab, an AI and machine learning platform, provides biotech companies with access to select Lilly models for drug discovery built on decades of Lilly's proprietary data.
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
Lilly reports third-quarter 2025 financial results, 30 Oct 2025
Announced an agreement to build the pharmaceutical industry's most powerful AI supercomputer, developing an "AI Factory" that will provide new AI capabilities to help scientists identify, optimize, and validate new molecules.
Eli Lilly and Company 2026 Proxy Statement (DEF 14A), incl. shareholder letter and CD&A, 20 Mar 2026
The lab's work is expected to begin in South San Francisco early this year.
Commitments made public in the last 12 months: 6
- Profluent AI-designed recombinase collaboration: Profluent to design site-specific recombinases with its AI models; Lilly receives exclusive licence to selected recombinases. New, announced, 28 Apr 2026. Published by: partner only.
- Insilico Medicine global R&D collaboration and licence (2026): Insilico grants Lilly exclusive licence to preclinical oral programmes and will collaborate on Lilly-selected targets using Pharma.AI. New, announced, 29 Mar 2026. Published by: partner release, company quoted.
- Lilly AI factory (LillyPod) and NVIDIA AI co-innovation lab: NVIDIA and Lilly announced a co-innovation AI lab linking Lilly agentic wet labs with computational dry labs. Expanded, announced, 12 Jan 2026. Published by: joint release.
- Chai Discovery biologics AI collaboration: Lilly to deploy Chai AI platform for biologics design; Chai to build a Lilly-exclusive model on Lilly data. New, announced, 12 Jan 2026. Published by: partner only.
- BigHat Biosciences antibody design collaboration: BigHat to generate antibody developability datasets for a TuneLab foundation model, expanding its Lilly relationship. Expanded, announced, 8 Jan 2026. Published by: partner only.
- Insilico Medicine research and licensing collaboration (from 2023 software licence): Insilico to design and optimise candidate compounds for Lilly-defined targets using Pharma.AI under a research and licensing collaboration. Expanded, announced, 10 Nov 2025. Published by: partner only.
Commitments made public in the year before: 6
- Lilly TuneLab federated AI/ML discovery platform: Lilly launched TuneLab, a federated AI/ML platform giving biotechs access to drug discovery models trained on Lilly data. New, operational, 9 Sep 2025. Published by: company.
- insitro-Lilly relationship (ADMET machine learning models): insitro to build ML models predicting small-molecule pharmacological properties, trained on Lilly preclinical data, for use via TuneLab. Expanded, announced, 9 Sep 2025. Published by: partner only.
- Superluminal Medicines GPCR discovery collaboration: Superluminal to apply its ML and structure-based platform to discover GPCR small molecules for Lilly. New, announced, 14 Aug 2025. Published by: partner only.
- Lilly-Purdue 360 Initiative (expanded Purdue alliance): Lilly and Purdue announced an expansion of their alliance with up to $250 million planned from Lilly over eight years; focus areas include AI-powered tools for drug discovery. Expanded, announced, 9 May 2025. Published by: joint release.
- BigHat Biosciences antibody design collaboration: Lilly to make an equity investment in BigHat, an ML-guided antibody discovery company, alongside the collaboration. New, announced, 17 Apr 2025. Published by: partner only.
- Chief AI Officer appointment (Thomas Fuchs): Lilly named Thomas Fuchs its first chief AI officer, with a remit covering AI in drug discovery, clinical trials and manufacturing; start date 21 October 2024. New, announced, 9 Oct 2024. Published by: media only.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 12
- Scientific Lead - Forward Deployed AI Engineer, Applied Intelligence for Discovery, San Francisco, California, United States of America
- Sr. AI Science Lead, South San Francisco, California, United States of America
- AI Scientist (Model Building & Training), South San Francisco, California, United States of America
- HPC Systems Administrator, South San Francisco, California, United States of America
- Director / Senior Director - Cheminformatics and Applied AI, Boston, Massachusetts, United States of America
- Advisor - Agentic Automation, Frontier AI, South San Francisco, California, United States of America
- Agentic Automation Lead - Frontier AI, South San Francisco, California, United States of America
- Staff Software Engineer, TuneLab, San Francisco, California, United States of America
- Senior Software Engineer, TuneLab, San Francisco, California, United States of America
- Chemical Reactivity Landscape, Scientific Project Leader, South San Francisco, California, United States of America
- Sr. Director of Strategic Partnerships, TuneLab Platform, San Francisco, California, United States of America
- AVP, AI/ML - Generative Foundation Models for Biotherapeutics, San Diego, California, United States of America
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: Lilly TuneLab, Hamilton, Tecan, Opentrons, LillyPod (NVIDIA Blackwell Ultra SuperPOD).
Asked for as experience: AWS, PyTorch, NVIDIA GPU infrastructure.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
What the company says: Priority 5
The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly's agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.
NVIDIA and Lilly will pioneer robotics and physical AI to accelerate and scale medicine discovery and production.
allowing them to work side by side to generate large-scale data and build powerful AI models that can accelerate medicine development
The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.
What it shows running: Delivery 2, funded or contracted
The collaboration will initially focus on creating a continuous learning system that tightly connects Lilly's agentic wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation to support biologists and chemists.
The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.
The two companies will invest up to $1 billion in talent, infrastructure and compute over five years to support the new AI co-innovation lab.
The lab's work is expected to begin in South San Francisco early this year.
Commitments made public in the last 12 months: 1
- Lilly AI factory (LillyPod) and NVIDIA AI co-innovation lab: NVIDIA and Lilly announced a co-innovation AI lab linking Lilly agentic wet labs with computational dry labs. Expanded, announced, 12 Jan 2026. Published by: joint release.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 13
- Lab Analytical Automation Scientist, Shanghai, Shanghai, China
- Advisor - Lab Automation Software Engineer, San Diego, California, United States of America
- Advisor - Lab Automation Software Engineer, AI-Integration, San Diego, California, United States of America
- RNA Automation Project Lead, Shanghai, Shanghai, China
- RNA Automation Specialist (NGS sequencing Focus), Shanghai, Shanghai, China
- RNA Automation Specialist (Biology Focus), Shanghai, Shanghai, China
- RNA Automation Specialist (Analytical Focus), Shanghai, Shanghai, China
- Advisor - Agentic Automation, Frontier AI, South San Francisco, California, United States of America
- Agentic Automation Lead - Frontier AI, South San Francisco, California, United States of America
- Chemical Reactivity Landscape, Scientific Project Leader, South San Francisco, California, United States of America
- Principal Platform Engineer - Research Data Platform, Bangalore, Karnātaka, India, posting since closed
- Dir/Sr. Dir - Lab Automation Engineer, Discovery Oncology, New York, New York, United States of America
- Advisor/Sr. Advisor - Automation Scientist, Discovery Oncology, New York, New York, United States of America
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: Hamilton, Tecan, Opentrons, AWS, Kubernetes, Docker, Kubernetes/EKS, Jenkins, Model Context Protocol (MCP).
Asked for as experience: Cellario.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- Lab automation and lab data roles sit in several units: biologics automation in San Diego, Discovery Oncology automation in New York, RNA and workcell automation in Shanghai, agentic automation linked to the NVIDIA co-innovation lab, and a research data platform team in Bangalore, several of them due to integrate with LIMS or ELN systems that no posting names. Who decides on scheduling software and LIMS or ELN integration, and how are the co-innovation lab's agentic systems linked to the site labs?
- Lilly has external AI discovery agreements with Chai, Insilico, Profluent, BigHat, insitro and Superluminal, while its own AI groups have dedicated capacity on LillyPod and TuneLab partner deals are announced by the partners. Who decides whether to license an external AI discovery platform rather than build on Lilly's own compute, do TuneLab partner deals go through the TuneLab team, business development or procurement, and how is funding set, including the up to $1 billion co-innovation lab commitment?
Coverage limits
Lilly's own websites blocked access, so its releases were read from PR Newswire copies, and anything Lilly published only on its own sites was missed. No annual report (Form 10-K) was read for either year, and results slides and call transcripts were not retrieved. Business Wire, GlobeNewswire and several partner and trade sites blocked access, and the search budget ran out before some newswire, venture portfolio and university searches, so the research labs and data counts rest mainly on the PR Newswire screen, results releases and two extra lab searches. Job postings were screened from the US-locale careers sitemap, which includes some roles outside the US; other locale sitemaps were not compared.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call